### **Overview** Fredun Pharmaceuticals Limited (FPL), established in 1987, is a leading Indian pharmaceutical and healthcare company with over 35 years of expertise in formulation manufacturing. Headquartered in Palghar, Maharashtra, the company has evolved from a traditional pharmaceutical exporter into a **holistic healthcare and wellness provider**, with a strategic pivot toward high-growth, consumer-centric verticals. FPL operates a multi-therapeutic, multi-product business model with a growing focus on **pet wellness, human nutrition, dermaceuticals, mobility aids, and specialty pharmaceuticals**. With a diversified portfolio of nearly **1,600–1,700 products**, strong in-house R&D, and a state-of-the-art manufacturing footprint, Fredun is expanding aggressively across domestic and international markets. The company is currently undergoing a **strategic transformation**, positioning itself to lead India’s rapidly scaling pet care and functional wellness sectors. --- ### **Core Business Segments & Strategic Diversification** #### **1. Generics Division (Fredun Gx)** - **Flagship business segment** and major revenue contributor. - Offers branded generics across **anti-diabetics, anti-hypertensives, anti-retrovirals, anti-infectives, antacids, anti-bacterials**, and other therapeutic categories. - Distributes in **17+ Indian states**, with strong institutional supply contracts from **Tamil Nadu Medical Services Corporation (TNMSC), Indian Railways, and the Defence sector**. - Secured **FY24 tender worth ~₹150 crore** for generic medicines. - Plans to derive **100% of revenues from vintage generics by FY29**, with over **51% of total revenue expected from the U.S. market by FY32**. #### **2. Pet Healthcare & Wellness (Freossi)** - Launched in 2021, **Freossi** has emerged as a first-mover in India's **organized pet healthcare market**. - Product range includes **MCHC-based supplements, functional pet food, pharmaceuticals, grooming, and diagnostics**. - MCHC (Microcrystalline Hydroxyapatite Complex) is a **core proprietary ingredient**, with over 60 years of clinical validation and **Fredun being India’s largest MCHC manufacturer**. - Key product milestones: - **Snacky Jain**: India’s first **pure Jain-certified functional pet snack**, launched in late 2024/early 2025. Sold out pre-orders, signaling strong market traction. - **FREOSSI Large Animals**: Targets livestock health with products like **Tone+** (for lactation) and **Power** (for joint support). - Expansion into **Sri Lanka** with 9 pet care products and pipeline of 20+. - **India’s first advanced 24x7 pet diagnostic center** launched under **Fredna Vet Diagnostics**, equipped with CBCT, CT scans, USG, and a pet ambulance. #### **3. Nutraceuticals (Fredun Nutrition)** - Positioned as **high-margin, science-backed wellness solutions** targeting chronic conditions (diabetes, cholesterol). - Differentiates through **double-blinded clinical trials** — a rare industry practice. - Key products: **Mamalait (lactation & immunity), Fredmax (energy & stamina), Damavand**. - Nutraceutical exports growing at **15% quarter-on-quarter**, with revenue exceeding **$2 million in FY24**. - Targeting expansion into Western and South Indian markets by FY26. #### **4. Cosmeceuticals (Bird n Beauty / Beautyfred)** - **Bird n Beauty (BnB)**: Premium line using **Emu Oil** (Omega 3, 6, 9) with **proprietary chemical-free purification**. Marketed ethically to dermatologists, sold via e-commerce. - **Beautyfred**: Mass-market brand with **200+ SKUs**; retail presence at **Mumbai’s railway and metro stations** — India’s first such retail model. - Focus on **skin, hair, and body care**, with products developed through in-house R&D and clinical trials. #### **5. Mobility & Ortho Aids (Fredun Medhora / BraceOn)** - Entered the mobility market in FY24 with **143+ SKUs**, now growing to **over 200**, targeting rehabilitation, post-surgery care, and chronic pain management. - Brands: **BraceOn, Chuu Balm, NebOn, DigiOn, Mobilitex**. - **Chuu Balm**, launched after 12 months of clinical trials, has achieved **strong penetration in tier-2 and tier-3 markets**. - Leverages **existing pharma distribution network** for fast market entry. - Projects **25–30% YoY growth** in the mobility segment. #### **6. Dermaceuticals & Bone Graft Technology** - **India’s only patented bone graft technology** using **deproteinized biocompatible xenograft (FREOSSI® Granules and Putty)**. - Based on high-collagen-content matrix, superior to synthetic alternatives. - Approved for **dental and maxillofacial use**, with **expansion into orthopedic applications underway**. - Positioned as a **high-margin specialty medical product**. --- ### **Strategic Acquisitions & Ecosystem Development** Fredun is building a **comprehensive pet wellness ecosystem**, integrating **products, services, diagnostics, and digital platforms**: #### **Acquisition of One Pet Stop (Jun–Jul 2025)** - Provides access to **4,000+ recurring pet owners** and a tech-enabled **doorstep grooming service**. - Operates with **PPGAI-certified professionals** using temperature-controlled vans. - Partnerships with **Dyson and Tropiclean** to elevate service quality. - Strengthens B2C service delivery and enables **subscription and wellness models**. #### **Acquisition of Wagr.ai / Wagr (Oct 2025)** - A **zero-cash deal** where Wagr’s founders and investors became equity partners in FPL. - Acquired Wagr’s **entire technology stack, customer database, patented hardware, software, and platform**: - **140,000+ registered pet parents** - **70+ partnered pet brands** - **20+ veterinary consultants** - **11,000+ teleconsultations completed (76 NPS)** - **Wagr.ai relaunch planned for Q4 FY2025–26** as: - **India’s first neutral online pet marketplace** — hosts all brands without proprietary competition. - Focuses on **functional food, wet food, and prescription diets**. - Features **GPS tracking, wearables, AI pet care advice (Toto chatbot), 24/7 vet teleconsultations, and AI diagnostics**. - All Wagr marketplace sales will be **recorded under FPL’s revenue**, enabling **direct-to-consumer control**. --- ### **Manufacturing & Infrastructure Expansion** - Operates a **multi-block, three-plant cluster in Palghar** spanning **allopathic, Ayurvedic, cosmetic, FSSAI, nutraceutical, and veterinary product manufacturing**. - WHO-GMP and PIC/s compliant; in process of achieving **PIC/s certification** for enhanced global regulatory acceptance. - **State-of-the-art facilities**: - **Dedicated nutraceutical, dermaceutical, and pet functional food unit** (commissioned Q2–Q3 FY26). - **Bone graft manufacturing plant** operational in FY24. - **Automated topical manufacturing**: Installed **two Italian tube filling machines**, increasing output capacity from 1.6 to ~4.5 tons/day. - **Advanced packaging machines** to automate cartoning and reduce labor. - **Expansion Goals**: - Become **one of India’s largest single-site pharmaceutical plants**. - Increase **outsourced manufacturing** from 5–7% to **15–20%** to leverage economies of scale and overcome MOQ/licensing constraints. - Add **37 third-party manufacturing sites** in 24 months. --- ### **Market Position & Growth Strategy** #### **Pet Care Market Opportunity** - **India’s pet care industry** projected to grow from **$1 billion (2021) to $6 billion by 2030** at **~22% CAGR**. - Segmented into: $900M (products), $250M (health), $200M (services). - Rising pet ownership (20 million pets), **urbanization, wellness awareness, and preventive care** drive demand. - FPL’s **Freossi aims to ensure every pet in India uses a FPL product/service by 2031**. #### **Digital & Ecosystem-Driven Strategy** - **Fully integrated pet wellness ecosystem** combining: - Science-backed nutrition (Snacky Jain) - Advanced diagnostics (Fredna Vet) - Service delivery (One Pet Stop) - Digital tech (Wagr.ai) - **AI-powered tools**: Toto (chatbot), telemedicine, GPS, wearables. - **Phygital model**: Blends digital reach with physical service access. - **Dedicated retail partnerships** across 8 Indian states. #### **Global Footprint** - Exports to **52+ countries** across **Africa, Southeast Asia, CIS, Latin America, MENA**. - **697+ final product registrations**, with over **1,200 in progress**. - Key export regions: Nigeria, Kenya, Vietnam, Malaysia, Sri Lanka, UAE. - **75% of exports are own-branded generics**, giving control over pricing and margins. --- ### **Financials & Performance Indicators** - **FY24 revenue**: ₹226.08 crore (up 68% YoY); **PAT: ₹6.3 crore** (from ₹2.0 crore). - **Non-pharma segments (Pet, Nutrition, Mobility, Cosmeceuticals)** are targeted to grow from ~3% (FY23) to **15–20% of total revenue by FY26**. - **Export revenue FY25**: ₹77.1 crore (FY25). - **EBITDA margin target**: 12–15% by FY26. - **Revenue CAGR guidance**: 25–30% over FY24–FY26. - **Record order book**: ₹197 crore (Nov 2025), ensuring **7 months of revenue visibility**. --- ### **R&D & Innovation** - Maintains a **dedicated F&D Lab** in Palghar established in FY2021 to support **1,000+ product registrations** over 4 years. - Focus on **first-of-their-kind veterinary molecules**, **Jain-certified food**, and **patented biomaterials**. - Conducts **double-blinded trials** for nutraceuticals and develops **proprietary formulations** using ethically sourced, high-purity raw materials. --- ### **ESG & Brand Ethos** - **Chuu Balm**: Positioned as **most potent and affordable**, targeting economically disadvantaged communities — blends **social responsibility with commercial potential**. - **Ethical marketing**: No forced prescriber incentives; products promoted through veterinary outreach and education. - Sustainable **phygital expansion** with low incremental capex due to **60%+ capacity utilization** and existing infrastructure.